1. Home
  2. FEAM vs BLRX Comparison

FEAM vs BLRX Comparison

Compare FEAM & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 5E Advanced Materials Inc.

FEAM

5E Advanced Materials Inc.

N/A

Current Price

$1.55

Market Cap

81.4M

Sector

Industrials

ML Signal

N/A

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

N/A

Current Price

$2.34

Market Cap

12.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FEAM
BLRX
Founded
2016
2003
Country
United States
Israel
Employees
35
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.4M
12.6M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
FEAM
BLRX
Price
$1.55
$2.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$6.38
$19.00
AVG Volume (30 Days)
217.6K
12.3K
Earning Date
05-14-2026
03-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.51
$2.28
52 Week High
$7.50
$7.77

Technical Indicators

Market Signals
Indicator
FEAM
BLRX
Relative Strength Index (RSI) 31.79 30.34
Support Level N/A N/A
Resistance Level $2.16 $3.93
Average True Range (ATR) 0.16 0.16
MACD 0.00 -0.03
Stochastic Oscillator 4.55 3.28

Price Performance

Historical Comparison
FEAM
BLRX

About FEAM 5E Advanced Materials Inc.

5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: